ERBB2 and breast cancer: It is well documented that the large gap in breast cancer survival between black and white women began in the 1980s, following the introduction of adjuvant endocrine therapy for ER+ breast cancer status and continued with subsequent therapies for PR+ and HER2+ subtypes[67].